Epoprostenol‐associated ascites in pulmonary arterial hypertension

The development of ascites in pulmonary arterial hypertension (PAH) in the absence of pre‐existing hepatic dysfunction is usually associated with decompensated right heart failure or cardiac cirrhosis. Ascites in PAH has rarely been associated with intravenous epoprostenol, a synthetic form of the p...

Full description

Saved in:
Bibliographic Details
Published inPulmonary circulation Vol. 12; no. 2; pp. e12092 - n/a
Main Authors Schoenberg, Noah C., Ruopp, Nicole F., Parikh, Raj D., Farber, Harrison W.
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.04.2022
John Wiley and Sons Inc
Wiley
Subjects
Ascites
Biopsy
Case Report
Case Reports
Diuretics
epoprostenol
Ethnicity
FDA approval
Females
Heart failure
Hemodynamics
Infections
Liver cirrhosis
Pathology
Patients
Permeability
Pulmonary hypertension
Sarcoidosis
ascites
epoprostenol
pulmonary hypertension
Online AccessGet full text

Cover

More Information
Summary:The development of ascites in pulmonary arterial hypertension (PAH) in the absence of pre‐existing hepatic dysfunction is usually associated with decompensated right heart failure or cardiac cirrhosis. Ascites in PAH has rarely been associated with intravenous epoprostenol, a synthetic form of the prostaglandin PGI2.
Bibliography:Noah C. Schoenberg and Nicole F. Ruopp are co‐authors.
ObjectType-Case Study-2
SourceType-Scholarly Journals-1
content type line 23
ObjectType-Report-1
ISSN:2045-8940
2045-8932
2045-8940
DOI:10.1002/pul2.12092